Is BPC-157 FDA Approved? Current Status

No. BPC-157 is not FDA approved for any human use. It is not approved as a drug, a dietary supplement ingredient or a bulk drug substance for compounding. The FDA has actively taken enforcement action against companies marketing BPC-157 with health claims. Here is the complete regulatory picture as of October 2026.

Short Answer, No, BPC-157 Is Not FDA Approved

What FDA Approval Means

FDA approval signifies that a substance has passed through clinical studies showing safety and efficacy for a particular purpose and that the FDA has evaluated and accepted this proof. This takes many years and costs millions of dollars. BPC-157 did not go through this process. No pharmaceutical company filed New Drug Application (NDA) or Investigational New Drug (IND) application for BPC-157 which would have authorized any product.

Why BPC-157 Does Not Have It

In order for the medicine to be approved, it needs controlled human trial data that it does not have. The base of evidence is mainly formed by various animal studies. In addition, BPC-157, being a peptide from a natural protein, might encounter difficulties in obtaining a patent, which would reduce the incentive of pharmaceutical companies to conduct costly clinical trials.

FDA Actions Regarding BPC-157

Warning Letters to Companies

The FDA has sent warning letters to firms selling BPC-157 goods with health claims. In these letters, violations of the Federal Food, Drug, and Cosmetic Act, in particular, the marketing of unapproved medicines, are alleged. The warning letters can be found publicly in the FDA warning letters database. Companies that receive these letters are told to stop making health claims and make their advertisements comply with the law.

The Compounding Pharmacy Question

Some compounding pharmacies began preparing BPC-157 formulations on a physician's prescription. The FDA's position on this has evolved. The agency evaluates whether compounds used in compounding meet the criteria for "bulk drug substances" under Section 503A and 503B of the FD&C Act. BPC-157 has been discussed in this context, and the FDA's Advisory Committee has weighed in. As of this writing, BPC-157 is not listed as an approved bulk drug substance for compounding.

Bulk Drug Substance Category

For a compound to be lawfully compounded, it must either be part of an FDA-approved medication or included in the FDA's course of confirmed bulk medication substances. BPC-157 is not included in either of those categories. So compounding pharmacies that sell BPC-157 might be working in a regulatory gray area, and the FDA has signaled its readiness to take action against this behavior.

1. 2022 FDA issues first warning letters to companies marketing BPC-157 with health claims
2. 2023 Additional enforcement actions and further warning letters
3. 2024 FDA Advisory Committee discusses BPC-157 compounding status
4. 2025 Continued monitoring and enforcement against unapproved marketing
5. 2026 BPC-157 remains unapproved; research-use-only labeling is the legal pathway

WADA and Sports Regulations

WADA Prohibited List Status

The World Anti-Doping Agency (WADA) has included BPC-157 on its prohibited list under the category of peptide hormones, growth factors and related substances (WADA Prohibited List). This classification applies at all times, both in and out of competition. Athletes subject to WADA-governed anti-doping programs cannot use BPC-157.

What This Means for Athletes

BPC-157's positive identification in an athlete would be regarded as an infringement of anti-doping regulations. As a result, an athlete would be suspended and barred from competing. The agency's decision to prohibit the use of BPC-157 is due to the drug's classification as a peptide.

State and International Law

US Federal vs. State Rules

BPC-157 is not controlled at the Federal level, and it is legal for researchers to buy or have the drug at their disposal. Since the legal problem comes up when products are being marketed or sold for human consumption with health claims, some states may have stricter regulations regarding peptide purchases, and laws are changing all the time.

How Other Countries Handle BPC-157

Regulatory approaches vary internationally. In Australia, the Therapeutic Goods Administration (TGA) classifies BPC-157 as a prescription-only substance, making it illegal to import without a prescription. In the UK, the MHRA has not specifically scheduled BPC-157 but regulates products making medicinal claims. The patchwork of international regulations means that legality depends on jurisdiction.

What Legal Purchase Actually Means

Research-Use Labeling

In the United States, the compound BPC-157 is sold legally when it is marked as "for research purposes only" or "not for consumption in human beings." The labeling is obligatory and reveals the legal position of the compound. Products of this compound can be purchased only for research purposes, and the sellers should demonstrate that their customers are aware of the limitation of use of this product.

The Difference Between Legal to Buy and Legal to Use

Many of the articles behind this site indicate the legality of buying a research chemical. However, the specific actions that you might take after that determine whether your subsequent actions fall under the law. Your personal use of research chemicals as an aid for your better health and wellbeing falls in a gray area. However, selling, promoting, or distributing research chemicals for others is clearly against the law since such activities involve FDA approval and regulation. It is crucial to understand the difference since we are not attorneys and do not provide any legal advice.